Improved Specificity and Safety of Anti-Hepatitis B Virus TALENs Using Obligate Heterodimeric
Animals
Animals, Outbred Strains
Antiviral Agents
/ therapeutic use
Cell Line
DNA Viruses
/ genetics
DNA, Circular
DNA, Viral
/ genetics
Deoxyribonucleases, Type II Site-Specific
/ genetics
Disease Models, Animal
Endonucleases
/ genetics
Female
Genetic Therapy
/ methods
HEK293 Cells
Hep G2 Cells
Hepatitis B
/ drug therapy
Hepatitis B virus
/ genetics
Hepatitis B, Chronic
/ genetics
Humans
Mice
Transcription Activator-Like Effector Nucleases
/ genetics
Virus Replication
/ genetics
HBV
Sharkey
cccDNA
obligate heterodimeric TALENs
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
12 07 2021
12 07 2021
Historique:
received:
18
06
2021
accepted:
02
07
2021
entrez:
10
8
2021
pubmed:
11
8
2021
medline:
18
9
2021
Statut:
epublish
Résumé
Persistent hepatitis B virus (HBV) infection remains a serious medical problem worldwide, with an estimated global burden of 257 million carriers. Prophylactic and therapeutic interventions, in the form of a vaccine, immunomodulators, and nucleotide and nucleoside analogs, are available. Vaccination, however, offers no therapeutic benefit to chronic sufferers and has had a limited impact on infection rates. Although immunomodulators and nucleotide and nucleoside analogs have been licensed for treatment of chronic HBV, cure rates remain low. Transcription activator-like effector nucleases (TALENs) designed to bind and cleave viral DNA offer a novel therapeutic approach. Importantly, TALENs can target covalently closed circular DNA (cccDNA) directly with the potential of permanently disabling this important viral replicative intermediate. Potential off-target cleavage by engineered nucleases leading to toxicity presents a limitation of this technology. To address this, in the context of HBV gene therapy, existing TALENs targeting the viral
Identifiants
pubmed: 34372550
pii: v13071344
doi: 10.3390/v13071344
pmc: PMC8310341
pii:
doi:
Substances chimiques
Antiviral Agents
0
DNA, Circular
0
DNA, Viral
0
Endonucleases
EC 3.1.-
Transcription Activator-Like Effector Nucleases
EC 3.1.-
endodeoxyribonuclease FokI
EC 3.1.21.-
Deoxyribonucleases, Type II Site-Specific
EC 3.1.21.4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Biochem Biophys Res Commun. 2000 Feb 24;268(3):728-33
pubmed: 10679273
Methods Mol Biol. 2010;649:247-56
pubmed: 20680839
Nat Biotechnol. 2007 Jul;25(7):778-85
pubmed: 17603475
Sci Rep. 2015 Sep 03;5:13734
pubmed: 26334116
Mol Ther. 2013 Oct;21(10):1889-97
pubmed: 23883864
Nucleic Acids Res. 2016 Jul 27;44(13):6482-92
pubmed: 27280977
Genes Cells. 2016 Nov;21(11):1253-1262
pubmed: 27659023
Nature. 2019 Dec;576(7785):149-157
pubmed: 31634902
Nat Methods. 2011 Aug 30;8(9):725-6
pubmed: 21878917
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558
pubmed: 30981686
Zebrafish. 2013 Sep;10(3):353-64
pubmed: 23781947
Cell. 1990 Dec 21;63(6):1357-63
pubmed: 2261646
J Mol Biol. 2010 Jul 2;400(1):96-107
pubmed: 20447404
Hepatology. 2017 Dec;66(6):2066-2077
pubmed: 28833361
Nucleic Acids Res. 2014 Apr;42(6):e42
pubmed: 24381193
Nat Methods. 2011 Jan;8(1):74-9
pubmed: 21131970
Nucleic Acids Res. 2014 Jun;42(10):6762-73
pubmed: 24792154
Adv Drug Deliv Rev. 2021 Jan;168:134-146
pubmed: 32485207
Genes (Basel). 2018 Apr 12;9(4):
pubmed: 29649127
J Hepatol. 2009 Sep;51(3):581-92
pubmed: 19616338
Nat Biotechnol. 2007 Jul;25(7):786-93
pubmed: 17603476
Biol Open. 2013 Dec 15;2(12):1364-70
pubmed: 24285709
Nucleic Acids Res. 2009 Jul;37(13):e91
pubmed: 19474340
Nat Biotechnol. 2019 Mar;37(3):224-226
pubmed: 30809026
Nat Biotechnol. 2014 Mar;32(3):279-284
pubmed: 24463574
J Virol. 2008 Aug;82(16):8013-21
pubmed: 18524822
Nat Commun. 2021 Jan 27;12(1):606
pubmed: 33504770
Nat Med. 2019 Feb;25(2):249-254
pubmed: 30692695
Mol Ther. 2016 Apr;24(4):671-7
pubmed: 26916283
Nat Biotechnol. 2019 Jun;37(6):657-666
pubmed: 30988504
Nucleic Acids Res. 2011 Nov;39(21):9283-93
pubmed: 21813459
Nat Biotechnol. 2019 Aug;37(8):945-952
pubmed: 31359006
Nat Med. 2019 Feb;25(2):242-248
pubmed: 30374197